EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtLeitlinie

Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines

Charalampos Charalampous, Darshi Shah, Shaji Kumar, Rajshekhar Chakraborty

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05733-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2024. Verfasst von Charalampos Charalampous und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Venous Thromboembolism, Anticoagulants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venous thromboembolism (VTE) poses a significant challenge in the context of multiple myeloma, with an incidence of up to 10% in newly diagnosed patients and varying frequency in the relapsed/refractory setting. Accurate VTE risk assessment and personalized thromboprophylaxis strategies are important parts of supportive care in myeloma. There are three validated risk assessment models for prediction of VTE risk in newly diagnosed myeloma-SAVED, IMPEDE-VTE, and PRISM. In this review, we delve into the practical applications of VTE risk prediction models in the context of current therapies. By emphasizing the necessity of a tailored approach, we underscore the importance of considering patient-specific, disease-specific, and treatment-specific risk factors in each clinical scenario, and using that data to complement the output from risk assessment models. We also provide a summary of currently available data on VTE thromboprophylaxis in myeloma, and highlight specific situations where direct oral anticoagulants should be strongly considered. Our objective is to fill the critical gaps in VTE prophylaxis and management through the analysis of specific patient cases and provide a practical overview for clinicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaVenous ThromboembolismAnticoagulantsHumansPractice Guidelines as TopicRisk FactorsMaleFemaleRisk AssessmentMiddle AgedAged

Stichwörter der Autor:innen

Multiple myelomaRisk factorsThromboprophylaxisThrombosisVenous thromboembolism

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.
  • Multiple Myeloma and Amyloidosis Program, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, USA. rc3360@cumc.columbia.edu.

Zitieren

APA

Charalampous, C., Shah, D., Kumar, S., & Chakraborty, R. (2024). Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines. Annals of Hematology. https://doi.org/10.1007/s00277-024-05733-9

Vancouver

Charalampous C, Shah D, Kumar S, Chakraborty R. Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines. Annals of Hematology. 2024. doi:10.1007/s00277-024-05733-9

BibTeX
@article{Charalampous2024,
  author = {Charalampous, Charalampos and Shah, Darshi and Kumar, Shaji and Chakraborty, Rajshekhar},
  title = {Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05733-9}
}
Kostenlos starten →